Premature and severe cardiovascular disease in a Mexican male with markedly low high-density-lipoprotein-cholesterol levels and a mutation in the lecithin:cholesterol acyltransferase gene: A family study

Posadas-Sánchez,Rosalinda; Posadas-Romero,Carlos; Ocampo-Arcos,Wendy Angélica; Villarreal-Molina,María Teresa; Vargas-Alarcón,Gilberto; Antúnez-Argüelles,Erika; Mendoza-Pérez,Enrique; Cardoso-Saldaña,Guillermo; Martínez-Alvarado,Rocío; Medina-Urrutia,Aída; Jorge-Galarza,Esteban

doi:10.3892/ijmm.2014.1733

Premature and severe cardiovascular disease in a Mexican male with markedly low high-density-lipoprotein-cholesterol levels and a mutation in the lecithin:cholesterol acyltransferase gene: A family study

Authors:
- Rosalinda Posadas-Sánchez
- Carlos Posadas-Romero
- Wendy Angélica Ocampo-Arcos
- María Teresa Villarreal-Molina
- Gilberto Vargas-Alarcón
- Erika Antúnez-Argüelles
- Enrique Mendoza-Pérez
- Guillermo Cardoso-Saldaña
- Rocío Martínez-Alvarado
- Aída Medina-Urrutia
- Esteban Jorge-Galarza
View Affiliations

Affiliations: Department of Endocrinology, National Institute of Cardiology ̔Ignacio Chávez̓ (INCICH), Tlalpan, Mexico City 14080, Mexico, Laboratory of Genomics of Cardiovascular Disease, National Institute of Genomic Medicine (INMEGEN), Tlalpan, Mexico City 14610, Mexico, Department of Molecular Biology, National Institute of Cardiology ̔Ignacio Chávez̓ (INCICH), Tlalpan, Mexico City 14080, Mexico
Published online on: April 7, 2014 https://doi.org/10.3892/ijmm.2014.1733
Pages: 1570-1576

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidemiological and clinical studies have shown that a low plasma high‑density lipoprotein cholesterol (HDL-C) level is a strong predictor of cardiovascular disease (CVD). Lecithin:cholesterol acyltransferase (LCAT) is a key enzyme in the formation, maturation and function of HDL. Therefore impaired LCAT function may enhance atherosclerosis because of defective cholesterol transport. In this study, we examined a 34-year old LCAT‑deficient patient and eight first-degree family members. There was a strong family history for CVD and type 2 diabetes mellitus (DM2). The proband was found homozygous for a previously reported LCAT gene mutation (Thr37Met). A sister and two sons of the proband were heterozygous for the same mutation. The proband had DM2 and showed severe multivessel coronary artery disease, corneal opacification and extremely low HDL-C levels. Large HDL particles were absent while small HDL particles were increased. The HDL of the patient had a reduced ability to promote cell cholesterol efflux, and the low‑density lipoproteins (LDL) were more susceptible to oxidation. Among his family members, two heterozygotes and one non-carrier had early carotid or coronary atherosclerosis. In conclusion, as the increased LDL oxidability and structural and functional abnormalities of HDL particles have been reported in patients with obesity and diabetes, the results suggested that the adverse coronary risk profile, and not being LCAT deficient, may be responsible for the CVD found in our proband, and for the early atherosclerosis observed in the two heterozygotes and in the wild‑type family members.

View Figures

View References

1	Gotto AM Jr and Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol. 43:717–724. 2004. View Article : Google Scholar : PubMed/NCBI
2	Breslow JL: Familial disorders of high density lipoprotein metabolism. The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS and Valle D: 7th editon. McGraw-Hill Publishing; New York: pp. 2031–2052. 1995
3	Assmann G, von Eckardstein A and Funke H: High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation. 87(Suppl 4): III28–III34. 1993.PubMed/NCBI
4	Glomset JA: The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 9:155–167. 1968.PubMed/NCBI
5	Howlader ZH, Kamiyama S, Shirakawa H, et al: Detoxification of oxidized LDL by transferring its oxidation product(s) to lecithin:cholesterol acyltransferase. Biochim Biophys Res Commun. 291:758–763. 2002. View Article : Google Scholar : PubMed/NCBI
6	Jonas A: Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 1529:245–256. 2000. View Article : Google Scholar
7	Kuivenhoven JA, Pritchard H, Hill J, et al: The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 38:191–205. 1997.PubMed/NCBI
8	Frohlich J, McLeod R, Pritchard PH, et al: Plasma lipoprotein abnormalities in heterozygotes for familial lecithin: cholesterol acyltransferase deficiency. Metabolism. 37:3–8. 1988. View Article : Google Scholar : PubMed/NCBI
9	Kasid A, Rhyne J, Zeller K, et al: A novel TC deletion resulting in Pro(260)-Stop in the human LCAT gene is associated with a dominant effect on HDL-cholesterol. Atherosclerosis. 156:127–132. 2001. View Article : Google Scholar : PubMed/NCBI
10	Kunnen S and Van Eck M: Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res. 53:1783–1799. 2012. View Article : Google Scholar : PubMed/NCBI
11	Asztalos BF, Schaefer EJ, Horvath KV, et al: Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res. 48:592–599. 2007. View Article : Google Scholar : PubMed/NCBI
12	Calabresi L, Pisciotta L, Costantin A, et al: The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 25:1972–1978. 2005. View Article : Google Scholar
13	Charlton-Menys V, Pisciotta L, Durrington PN, et al: Molecular characterization of two patients with severe LCAT deficiency. Nephrol Dial Transplant. 22:2379–2382. 2007. View Article : Google Scholar : PubMed/NCBI
14	Bérard AM, Clerc M, Brewer B Jr and Santamarina-Fojo S: A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Clin Chim Acta. 314:131–139. 2001.PubMed/NCBI
15	Hovingh GK, Hutten BA, Holleboom AG, et al: Compromised LCAT function is associated with increased atherosclerosis. Circulation. 112:879–884. 2005. View Article : Google Scholar : PubMed/NCBI
16	Calabresi L, Baldassarre D, Castelnuovo S, et al: Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 120:628–635. 2009. View Article : Google Scholar : PubMed/NCBI
17	Medina-Urrutia A, Juarez-Rojas JG, Martínez-Alvarado R, et al: High-density lipoprotein subclasses distribution and composition in Mexican adolescents with low HDL cholesterol and/or high triglyceride concentrations, and its association with insulin and C-reactive protein. Atherosclerosis. 201:392–397. 2008. View Article : Google Scholar
18	Chen CH and Albers JJ: Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase activity. J Lipid Res. 23:680–691. 1982.PubMed/NCBI
19	Posadas-Sánchez R, Posadas-Romero C, Zamora-González J, et al: LDL size and susceptibility to oxidation in experimental nephrosis. Mol Cell Biochem. 220:61–68. 2001.
20	Eckerson HW, Wyte CM, LA and la Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 35:1126–1138. 1983.PubMed/NCBI
21	De la Llera-Moya M, Atger V, Paul JL, et al: A cell system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb Vasc Biol. 14:1056–1065. 1994.PubMed/NCBI
22	De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al: The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 30:796–801. 2010.PubMed/NCBI
23	Stein JH, Korcarz CE, Hurst RT, et al; American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 21:93–111. 2008.
24	Mautner GC, Mautner SL, Froehlich J, et al: Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. Radiology. 192:619–623. 1994. View Article : Google Scholar : PubMed/NCBI
25	Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI
26	Argyropoulos G, Jenkins A, Klein RL, et al: Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband. J Lipid Res. 39:1870–1876. 1998.
27	Posadas-Sánchez R, Posadas-Romero C, Mendoza-Pérez E, et al: Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low density lipoprotein-cholesterol <70 mg/dl. Am J Cardiol. 5:636–641. 2012.PubMed/NCBI
28	Santamarina-Fojo S, Hoeg JM, Assmann G, et al: Lecithin Cholesterol Acyltransferase Deficiency and Fish Eye Disease. The Metabolic and MolecularBases of Inherited Diseases. Scriver CR, Beaud, Sly WS, Valle D, et al: McGraw-Hill Publishing; New York: pp. 2817–2833. 2001
29	Rader DJ, Ikewaki K, Duverger N, et al: Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest. 93:321–330. 1994. View Article : Google Scholar
30	Kelso GJ, Stuart WD, Richter RJ, et al: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:832–839. 1994. View Article : Google Scholar : PubMed/NCBI
31	Mackness MI, Arrol S and Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:152–154. 1991. View Article : Google Scholar : PubMed/NCBI
32	Watson AD, Berliner JA, Hama SY, et al: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 96:2882–2891. 1995. View Article : Google Scholar : PubMed/NCBI
33	Mackness MI, Walker CH and Carlson LA: Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem. 33:587–588. 1987.PubMed/NCBI
34	Huang Y, von Eckardstein A, Wu S, et al: A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA. 91:1834–1838. 1994. View Article : Google Scholar : PubMed/NCBI
35	Durrington PN, Mackness B and Mackness MI: The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol. 22:1248–1250. 2002. View Article : Google Scholar : PubMed/NCBI
36	Ferré N, Camps J, Fernández-Ballart J, et al: Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem. 49:1491–1497. 2003.PubMed/NCBI
37	Calabresi L, Favari E, Moleri E, et al: Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis. 204:141–146. 2009. View Article : Google Scholar : PubMed/NCBI
38	Nishiwaki M, Ikewaki K, Bader G, et al: Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol. 26:1370–1375. 2006. View Article : Google Scholar : PubMed/NCBI
39	Savel J, Lafitte M, Pucheu Y, et al: Very low levels of HDL cholesterol and atherosclerosis, a variable relationship-a review of LCAT deficiency. Vasc Health Risk Manag. 8:357–361. 2012.PubMed/NCBI
40	Duivenvoorden R, Holleboom AG, van den Bogaard B, et al: Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging. J Am Coll Cardiol. 58:2481–2487. 2011. View Article : Google Scholar : PubMed/NCBI
41	El Harchaoui K, Arsenault BJ, Franssen R, et al: High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 150:84–93. 2009.PubMed/NCBI
42	Syvänne M, Castro G, Dengremont C, et al: Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis. 127:245–253. 1996.